CN116472061A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN116472061A
CN116472061A CN202180073514.8A CN202180073514A CN116472061A CN 116472061 A CN116472061 A CN 116472061A CN 202180073514 A CN202180073514 A CN 202180073514A CN 116472061 A CN116472061 A CN 116472061A
Authority
CN
China
Prior art keywords
amino acid
pharmaceutical composition
seq
antibody
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180073514.8A
Other languages
English (en)
Chinese (zh)
Inventor
渡边洋介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN116472061A publication Critical patent/CN116472061A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202180073514.8A 2020-10-30 2021-10-28 药物组合物 Pending CN116472061A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020182606 2020-10-30
JP2020-182606 2020-10-30
PCT/JP2021/039769 WO2022092183A1 (ja) 2020-10-30 2021-10-28 医薬組成物

Publications (1)

Publication Number Publication Date
CN116472061A true CN116472061A (zh) 2023-07-21

Family

ID=81381503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180073514.8A Pending CN116472061A (zh) 2020-10-30 2021-10-28 药物组合物

Country Status (6)

Country Link
US (1) US20230338522A1 (https=)
EP (1) EP4238578A4 (https=)
JP (1) JPWO2022092183A1 (https=)
CN (1) CN116472061A (https=)
TW (1) TW202227483A (https=)
WO (1) WO2022092183A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079496A1 (en) * 2005-01-26 2006-08-03 Lek Pharmaceuticals D.D. New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
JP4881268B2 (ja) * 2006-09-25 2012-02-22 あすか製薬株式会社 苦味が抑制された経口製剤
NZ595526A (en) * 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP3159007A1 (en) * 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017193541A (ja) * 2016-04-19 2017-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP7490329B2 (ja) 2016-10-14 2024-05-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
WO2018201064A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
US20220205980A1 (en) * 2019-04-23 2022-06-30 Eisai R&D Management Co., Ltd. Biomarker for rheumatoid arthritis treatment

Also Published As

Publication number Publication date
JPWO2022092183A1 (https=) 2022-05-05
TW202227483A (zh) 2022-07-16
WO2022092183A1 (ja) 2022-05-05
EP4238578A1 (en) 2023-09-06
US20230338522A1 (en) 2023-10-26
EP4238578A4 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
TWI578998B (zh) 抗ｉｌ－６受體的抗體
US11179463B2 (en) BLyS antibody formulation
KR101468271B1 (ko) 개량된 항체분자를 함유하는 의약 제제
ES2923143T3 (es) Anticuerpos monoclonales antagonistas contra CD40 y sus usos
KR102385802B1 (ko) Gm-csf 중화 화합물을 포함하는 액체 제제
TW201200152A (en) Novel antibody formulation
CN114981307B (zh) 抗btla抗体药物组合物及其用途
AU2014209994A1 (en) TNF-alpha antigen-binding proteins
TW202003570A (zh) 抗trem-1抗體及其用途
KR20230122034A (ko) 단백질 제형물 및 이의 용도
JP2020515577A (ja) 免疫原性の低下のための方法及び組成物
KR20170106476A (ko) Cd154 항체를 이용한 자가면역 질환의 치료
KR20150075083A (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
CA3235879A1 (en) Pharmaceutical formulation comprising anti-ox40 monoclonal antibody
CN116472061A (zh) 药物组合物
JP2020521788A (ja) 免疫アゴニストの投与経路
CN117597365A (zh) 多特异性fgf21受体激动剂及其应用
EP3159007A1 (en) Pharmaceutical composition for treating rheumatoid arthritis
CN113966230B (zh) 抗csf1r分子及其用途
WO2025217676A1 (en) Protein formulations and uses thereof
HK40065889B (zh) 抗csf1r分子及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination